What does this research mean for the field?

Payment reductions achieved during the Oncology Care Model were sustained for 18 months after the model ended, generating $328 million in additional savings driven predominantly by practices that adopted two-sided risk. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to assess whether the payment reductions achieved during the Oncology Care Model continued for 18 months after its conclusion.

May 17, 2026Health Services Research

Sustained Impacts in the Oncology Care Model: Medicare Payment Impacts in the 18 Months After the Model's End

View Full Paper

Ask AI

Bookmark

Authors

DHDerek Hoodin SMSean McClellan NCNadine Chami

Discussion

Member takes

Overview

Randomized trial evaluates sustained payment reductions in Medicare beneficiaries receiving chemotherapy, indicating ongoing cost savings.

Key Points

This research aims to assess whether the payment reductions achieved during the Oncology Care Model continued for 18 months after its conclusion.
Extended regression-adjusted difference-in-differences (DID) analysis for OCM payments.
Reviewed Medicare administrative data from January 2014 to June 2023.
Focused on total episode payments (TEP) and component payments, including Parts A, B, and D.
In the 18 months post-OCM, TEP reduced by an average of −$955, with significant reductions in Part B payments (−$559).
Payment reductions totaled $328 million, primarily from practices adopting two-sided risk, which saw TEP drop by $3379.
Practices under two-sided risk also reduced Payments in Parts A (−$738), B (−$1370), and D (−$1112).

Cite This Study

Hoodin et al. (2026) studied this question.

synapsesocial.com/papers/6a095c037880e6d24efe1fb4 https://doi.org/10.1111/1475-6773.70121

View Full Paper

Ask AI

Bookmark

May 17, 2026Health Services Research

Sustained Impacts in the Oncology Care Model: Medicare Payment Impacts in the 18 Months After the Model's End

View Full Paper

Ask AI

Bookmark

Authors

DHDerek Hoodin SMSean McClellan NCNadine Chami

Discussion

Member takes

Overview

Randomized trial evaluates sustained payment reductions in Medicare beneficiaries receiving chemotherapy, indicating ongoing cost savings.

Key Points

This research aims to assess whether the payment reductions achieved during the Oncology Care Model continued for 18 months after its conclusion.
Extended regression-adjusted difference-in-differences (DID) analysis for OCM payments.
Reviewed Medicare administrative data from January 2014 to June 2023.
Focused on total episode payments (TEP) and component payments, including Parts A, B, and D.
In the 18 months post-OCM, TEP reduced by an average of −$955, with significant reductions in Part B payments (−$559).
Payment reductions totaled $328 million, primarily from practices adopting two-sided risk, which saw TEP drop by $3379.
Practices under two-sided risk also reduced Payments in Parts A (−$738), B (−$1370), and D (−$1112).

Cite This Study

Hoodin et al. (2026) studied this question.

synapsesocial.com/papers/6a095c037880e6d24efe1fb4 https://doi.org/10.1111/1475-6773.70121

View Full Paper

Ask AI

Bookmark